Targeting neuropilins as a viable SARS‐CoV‐2 treatment

The SARS‐CoV‐2 pandemic has significantly impacted global health. Research on viral mechanisms, highly effective vaccines, and other therapies is in progress. Neuropilins have recently been identified as host cell receptors enabling viral fusion. Here, we provide context to neuropilin's tissue‐specific role in infection and the potential impact of NRP‐based therapeutics. We conclude that the central roles of neuropilins in vascular, neural, and other pathways may render it a less suitable target for treating SARS‐CoV‐2 than agents that target its binding partner, the viral spike protein.